dyskinesias

Summary

Summary: Abnormal involuntary movements which primarily affect the extremities, trunk, or jaw that occur as a manifestation of an underlying disease process. Conditions which feature recurrent or persistent episodes of dyskinesia as a primary manifestation of disease may be referred to as dyskinesia syndromes (see MOVEMENT DISORDERS). Dyskinesias are also a relatively common manifestation of BASAL GANGLIA DISEASES.

Top Publications

  1. ncbi A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease
    C Warren Olanow
    Department of Neurology, Mount Sinai School of Medicine, One Gustave L Levy Place, New York, NY 10029, USA
    Ann Neurol 54:403-14. 2003
  2. pmc Selective inhibition of striatal fast-spiking interneurons causes dyskinesias
    Aryn H Gittis
    Gladstone Institute of Neurological Disease, San Francisco, California 94158, USA
    J Neurosci 31:15727-31. 2011
  3. ncbi Continuous jejunal levodopa infusion in patients with advanced parkinson disease: practical aspects and outcome of motor and non-motor complications
    Karla Eggert
    Department of Neurology, Philipps University of Marburg, Marburg, Germany
    Clin Neuropharmacol 31:151-66. 2008
  4. ncbi Novel GCH-1 mutations and unusual long-lasting dyskinesias in Korean families with dopa-responsive dystonia
    Jee Young Lee
    Department of Neurology, SMG SNU Boramae Medical Center, Seoul, South Korea
    Parkinsonism Relat Disord 19:1156-9. 2013
  5. ncbi PET demonstrates reduced dopamine transporter expression in PD with dyskinesias
    A R Troiano
    Pacific Parkinson s Research Centre, Vancouver, BC, Canada
    Neurology 72:1211-6. 2009
  6. ncbi Dopaminergic treatment is associated with decreased body weight in patients with Parkinson's disease and dyskinesias
    C G Bachmann
    Department of Clinical Neurophysiology, Georg August University, Gottingen, Germany
    Eur J Neurol 16:895-901. 2009
  7. pmc Amantadine for dyskinesias in Parkinson's disease: a randomized controlled trial
    Hideyuki Sawada
    Clinical Research Center, Utano National Hospital, Kyoto City, Japan
    PLoS ONE 5:e15298. 2010
  8. ncbi Subthalamic stimulation-induced forelimb dyskinesias are linked to an increase in glutamate levels in the substantia nigra pars reticulata
    Sabrina Boulet
    Dynamique des Réseaux Neuronaux, Institut National de la Sante et de la Recherche Medicale, Unité 704, F 38041 Grenoble, France
    J Neurosci 26:10768-76. 2006
  9. ncbi Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes
    Galit Kleiner-Fisman
    Parkinson s Disease Research Education and Clinical Center, Philadelphia VA Hospital, Philadelphia, Pennsylvania 19104, USA
    Mov Disord 21:S290-304. 2006
  10. ncbi Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study
    M Pechevis
    Cemka Eval, Bourg la Reine, France
    Eur J Neurol 12:956-63. 2005

Detail Information

Publications217 found, 100 shown here

  1. ncbi A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease
    C Warren Olanow
    Department of Neurology, Mount Sinai School of Medicine, One Gustave L Levy Place, New York, NY 10029, USA
    Ann Neurol 54:403-14. 2003
    ..Fetal nigral transplantation currently cannot be recommended as a therapy for PD based on these results...
  2. pmc Selective inhibition of striatal fast-spiking interneurons causes dyskinesias
    Aryn H Gittis
    Gladstone Institute of Neurological Disease, San Francisco, California 94158, USA
    J Neurosci 31:15727-31. 2011
    ..These results provide direct evidence that hypofunction of striatal FSIs can produce movement abnormalities, and suggest that they may represent a novel therapeutic target for the treatment of hyperkinetic movement disorders...
  3. ncbi Continuous jejunal levodopa infusion in patients with advanced parkinson disease: practical aspects and outcome of motor and non-motor complications
    Karla Eggert
    Department of Neurology, Philipps University of Marburg, Marburg, Germany
    Clin Neuropharmacol 31:151-66. 2008
    ..The tolerability, efficacy, and the need for dose adjustment of levodopa infusion were followed-up prospectively. Thereby, we describe clinically relevant details for how to successfully initiate and handle this new treatment strategy...
  4. ncbi Novel GCH-1 mutations and unusual long-lasting dyskinesias in Korean families with dopa-responsive dystonia
    Jee Young Lee
    Department of Neurology, SMG SNU Boramae Medical Center, Seoul, South Korea
    Parkinsonism Relat Disord 19:1156-9. 2013
    To describe the long-term follow-up data of Korean patients with GTP cyclohydrolase (GTPCH) I deficient dopa-responsive dystonia (DRD) with novel mutations and unusual long-lasting dyskinesias.
  5. ncbi PET demonstrates reduced dopamine transporter expression in PD with dyskinesias
    A R Troiano
    Pacific Parkinson s Research Centre, Vancouver, BC, Canada
    Neurology 72:1211-6. 2009
    b>Dyskinesias are common in Parkinson disease (PD). Prior investigations suggest that dopamine (DA) terminals compensate for abnormal DA transmission...
  6. ncbi Dopaminergic treatment is associated with decreased body weight in patients with Parkinson's disease and dyskinesias
    C G Bachmann
    Department of Clinical Neurophysiology, Georg August University, Gottingen, Germany
    Eur J Neurol 16:895-901. 2009
    ..We aimed to investigate whether PD patients with dyskinesias display body weight alterations and to observe any correlations between medication and other putative ..
  7. pmc Amantadine for dyskinesias in Parkinson's disease: a randomized controlled trial
    Hideyuki Sawada
    Clinical Research Center, Utano National Hospital, Kyoto City, Japan
    PLoS ONE 5:e15298. 2010
    b>Dyskinesias are some of the major motor complications that impair quality of life for patients with Parkinson's disease...
  8. ncbi Subthalamic stimulation-induced forelimb dyskinesias are linked to an increase in glutamate levels in the substantia nigra pars reticulata
    Sabrina Boulet
    Dynamique des Réseaux Neuronaux, Institut National de la Sante et de la Recherche Medicale, Unité 704, F 38041 Grenoble, France
    J Neurosci 26:10768-76. 2006
    ..These new neurochemical data suggest that STN-HFS-induced forelimb dyskinesia is mediated by glutamate, probably via the direct activation of STN axons, shedding light on the mechanisms of STN-HFS in PD...
  9. ncbi Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes
    Galit Kleiner-Fisman
    Parkinson s Disease Research Education and Clinical Center, Philadelphia VA Hospital, Philadelphia, Pennsylvania 19104, USA
    Mov Disord 21:S290-304. 2006
    ..These data provide an estimate of the magnitude of the treatment effects and emphasize the need for controlled and randomized studies...
  10. ncbi Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study
    M Pechevis
    Cemka Eval, Bourg la Reine, France
    Eur J Neurol 12:956-63. 2005
    The treatment of Parkinson's disease (PD) with l-DOPA leads to involuntary movements (dyskinesias)...
  11. ncbi Increased slow oscillatory activity in substantia nigra pars reticulata triggers abnormal involuntary movements in the 6-OHDA-lesioned rat in the presence of excessive extracellular striatal dopamine
    Wassilios Meissner
    Laboratoire de Physiologie et Physiopathologie de la Signalisation Cellulaire, CNRS UMR 5543, Universite Victor Segalen, 146 rue Leo Saignat, 33076 Bordeaux Cedex, France
    Neurobiol Dis 22:586-98. 2006
    ....
  12. ncbi Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges
    Regina Katzenschlager
    Reta Lila Weston Institute of Neurological Studies, University College London, United Kingdom
    Mov Disord 20:151-7. 2005
    ..SC) infusion of the dopamine agonist apomorphine was shown in retrospective studies to improve drug-induced dyskinesias in Parkinson's disease (PD)...
  13. ncbi Spontaneous movement disorders in antipsychotic-naive patients with first-episode psychoses: a systematic review
    S Pappa
    Institute of Psychiatry, Division of Psychological Medicine, King s College London, UK
    Psychol Med 39:1065-76. 2009
    ..Their presence has been documented extensively in chronic schizophrenia but not at the time of illness onset...
  14. pmc Impact of dendritic spine preservation in medium spiny neurons on dopamine graft efficacy and the expression of dyskinesias in parkinsonian rats
    Katherine E Soderstrom
    Department of Neurological Sciences, Rush University Medical Center, Chicago, IL 60612, USA
    Eur J Neurosci 31:478-90. 2010
    ..However, analyses of vibrissae-induced forelimb use, levodopa-induced dyskinesias and graft-induced dyskinesias showed significant improvement in rats with dopamine grafts associated with ..
  15. pmc RAD51 haploinsufficiency causes congenital mirror movements in humans
    Christel Depienne
    INSERM, U CRICM, Hopital Pitie Salpetriere, Paris, France
    Am J Hum Genet 90:301-7. 2012
    ..These findings open a new field of investigation for researchers attempting to unravel the molecular pathways underlying bimanual motor control in humans...
  16. ncbi Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease
    Urszula Adamiak
    Departments of Pharmacokinetics and Therapeutic Drug Monitoring, Pomeranian Medical University, Szczecin, Poland
    Clin Neuropharmacol 33:135-41. 2010
    ..pk/pd) relationship of levodopa (l-dopa) in patients with advanced Parkinson disease (PD) and also to evaluate the effect of tolcapone on the pk/pd analysis of l-dopa in 1 patient with severe dyskinesias and fluctuations.
  17. ncbi Spontaneous dyskinesia and parkinsonism in never-medicated, chronically ill patients with schizophrenia: 18-month follow-up
    R G McCreadie
    Crichton Royal Hospital, Dumfries, UK
    Br J Psychiatry 181:135-7. 2002
    ..Spontaneous dyskinesia and parkinsonism have been reported in never-medicated patients with schizophrenia but there has been no previous study of the natural history of these conditions...
  18. ncbi Subthalamic activity during diphasic dyskinesias in Parkinson's disease
    Manuel Alegre
    Neurosciences Area, CIMA, University of Navarra, Pamplona, Spain
    Mov Disord 27:1178-81. 2012
    Diphasic dyskinesias are a subtype of levodopa-induced dyskinesias that appear typically at the onset and end of levodopa antiparkinsonian action. The pathophysiology of diphasic dyskinesias is not well understood.
  19. ncbi [Effects of traditional Chinese herbal medicine on the neurobehavioral manifestations and the activity of dopamine D2 receptor in corpora striatum of rats with levodopa-induced dyskinesias]
    Can Xing Yuan
    Department of Neurology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China
    Zhong Xi Yi Jie He Xue Bao 6:1024-8. 2008
    ..herbal medicine (TCM) for nourishing liver and kidney, clearing meridians and removing toxic substances, on the neurobehavioral manifestations and the activity of the dopamine D2 receptor in rat with levodopa-induced dyskinesias (LID).
  20. pmc Dyskinesias as a limiting factor in the treatment of Segawa disease
    Eduardo Lopez-Laso
    Pediatric Neurology Unit, Department of Pediatrics, University Hospital Reina Sofia, Maimónides Institute of Biomedical Research of Córdoba, University of Cordoba, Cordoba, Spain
    Pediatr Neurol 46:404-6. 2012
    ..In contrast, the development of levodopa limiting treatment dyskinesias is thought to support the diagnosis of other early-onset dystonia/parkinsonism syndromes...
  21. ncbi Levodopa-induced dyskinesias and their management
    Francesca Del Sorbo
    Fondazione IRCCS Istituto Neurologico Carlo Besta, Via G Celoria, 11, 20133, Milano, Italy
    J Neurol 255:32-41. 2008
    This paper reviews the epidemiology, pathophysiology, clinical features and rationale for managing dyskinesias associated with Parkinson's disease...
  22. ncbi Naltrexone in the short-term decreases antiparkinsonian response to l-Dopa and in the long-term increases dyskinesias in drug-naïve parkinsonian monkeys
    Pershia Samadi
    Centre de Recherche en Neurosciences, CHUL Sainte Foy, Quebec, Canada
    Neuropharmacology 49:165-73. 2005
    ..l-Dopa plus naltrexone the beginning of the therapeutical effect of l-Dopa was accompanied by the appearance of dyskinesias. In this group, the severity of dyskinesias during the third and fourth weeks of treatment was significantly ..
  23. ncbi Dyskinesia after fetal cell transplantation for parkinsonism: a PET study
    Yilong Ma
    Center for Neurosciences, North Shore Long Island Jewish Research Institute and Department of Neurology, North Shore University Hospital, 350 Community Drive, Manhasset, NY 11030, USA
    Ann Neurol 52:628-34. 2002
    Persistent dyskinesias in the absence of or with only minimal amounts of dopaminergic medication have been reported after dopamine cell implantation for Parkinson's disease...
  24. pmc Brief report: autistic symptoms, developmental regression, mental retardation, epilepsy, and dyskinesias in CNS folate deficiency
    Paolo Moretti
    Department of Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
    J Autism Dev Disord 38:1170-7. 2008
    ..These findings demonstrate that autistic features are salient in CFD and suggest that a subset of children with developmental regression, mental retardation, seizures, dyskinesia, and autism may have CNS folate abnormalities...
  25. pmc Dyskinesias and associated psychiatric disorders following streptococcal infections
    R C Dale
    Neurosciences Unit, Institute of Child Health and Great Ormond Street Hospital for Children NHS Trust, London, UK
    Arch Dis Child 89:604-10. 2004
    ..Recently, other post-streptococcal movement disorders have been described, including motor tics and dystonia. Associated emotional and behavioural alteration is characteristic...
  26. ncbi Rat model of Parkinson's disease with bilateral motor abnormalities, reversible with levodopa, and dyskinesias
    Vincent Paille
    INSERM, UMR 643 and Institut de Transplantation et de Recherche en Transplantation, CHU, Nantes, France
    Mov Disord 22:533-9. 2007
    ..After a few years, the beneficial effect of the treatment is frequently offset by the development of dyskinesias. To improve treatment strategies, an animal model showing most of the histological and clinical characteristics ..
  27. ncbi Levodopa-induced dyskinesias detection based on the complexity of involuntary movements
    Mircea I Chelaru
    Clinical Neurological Sciences, University of Western Ontario, London, Ontario, Canada
    J Neurosci Methods 186:81-9. 2010
    ..The clear difference between the sample entropy-based measures for the non-dyskinetic and dyskinetic patients made possible the automatic, efficient recognition of the dyskinetic condition, based on multi-layer perceptrons...
  28. ncbi Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-induced dyskinesias
    Belen Ferrer
    Fundacion Hospital Carlos Haya, 29010 Malaga, Spain
    Eur J Neurosci 18:1607-14. 2003
    The majority of Parkinson's disease patients undergoing levodopa therapy develop disabling motor complications (dyskinesias) within 10 years of treatment...
  29. pmc Markers of basal ganglia dysfunction and conversion to psychosis: neurocognitive deficits and dyskinesias in the prodromal period
    Vijay A Mittal
    Department of Psychology, University of California Los Angeles, Los Angeles, California, USA
    Biol Psychiatry 68:93-9. 2010
    ....
  30. ncbi Relevance of the MPTP primate model in the study of dyskinesia priming mechanisms
    Pierre J Blanchet
    Department of Stomatology, Faculty of Dental Medicine, University of Montreal, Que, Canada
    Parkinsonism Relat Disord 10:297-304. 2004
    ..Studies indicate that sustained dopamine D2 receptor occupancy can prevent and reverse existing dyskinesias. Recent experiments in levodopa-treated MPTP animals, co-administered either a threshold dose of cabergoline or ..
  31. ncbi Increases in striatal preproenkephalin gene expression are associated with nigrostriatal damage but not L-DOPA-induced dyskinesias in the squirrel monkey
    M Quik
    The Parkinson s Institute, 1170 Morse Avenue, Sunnyvale, CA 94089, USA
    Neuroscience 113:213-20. 2002
    ..in the caudate and putamen have been linked to the development of L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesias in primate models of Parkinson's disease, although not all investigators have been able to confirm this ..
  32. ncbi Spontaneous dyskinesia in first-episode psychosis in a Southeast Asian population
    Jimmy Lee
    Institute of Mental Health Woodbridge Hospital, Singapore
    J Clin Psychopharmacol 28:536-9. 2008
    ..Patients with dyskinetic movements at baseline could have a more treatment refractory course of illness...
  33. ncbi Topography of dyskinesias and torticollis evoked by inhibition of substantia nigra pars reticulata
    David Dybdal
    Department of Pharmacology and Physiology, Georgetown University Medical Center, Washington, DC 20007, USA
    Mov Disord 28:460-8. 2013
    ..In monkeys, choreiform limb dyskinesias have been described after inhibition of the GPi, but not the SNpr...
  34. ncbi New pharmacological avenues for the treatment of L-DOPA-induced dyskinesias in Parkinson's disease: targeting glutamate and adenosine receptors
    Fabio Blandini
    IRCCS National Neurological Institute C Mondino, Interdepartmental Research Center for Parkinson s Disease, Via Mondino 2, 27100 Pavia, Italy
    Expert Opin Investig Drugs 21:153-68. 2012
    ..which is hampered by numerous side effects, including abnormal involuntary movements known as L-DOPA-induced dyskinesias (LIDs)...
  35. pmc Optimized adeno-associated viral vector-mediated striatal DOPA delivery restores sensorimotor function and prevents dyskinesias in a model of advanced Parkinson's disease
    Tomas Bjorklund
    Brain Repair and Imaging in Neural Systems, 22184 Lund, Sweden
    Brain 133:496-511. 2010
    ..This approach has been shown to be efficient in restoring motor function and reducing established dyskinesias in rats with a partial lesion of the nigrostriatal dopamine projection...
  36. ncbi Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial
    Christopher G Goetz
    Rush University Medical Center, Chicago, Illinois 60612, USA
    Mov Disord 22:179-86. 2007
    ..Included were PD patients optimized to levodopa and dopaminergic drugs with moderately disabling dyskinesias present greater than or equal to 25% of the waking day...
  37. ncbi Serotonergic neurons mediate dyskinesia side effects in Parkinson's patients with neural transplants
    Marios Politis
    Centre for Neuroscience, Division of Experimental Medicine, Faculty of Medicine, Hammersmith Hospital, Imperial College London, London W12 0NN, UK
    Sci Transl Med 2:38ra46. 2010
    Troublesome involuntary movements in the absence of dopaminergic medication, so-called off-medication dyskinesias, are a serious adverse effect of fetal neural grafts that hinders the development of cell-based therapies for Parkinson's ..
  38. ncbi Graft-induced dyskinesias in Parkinson's disease: High striatal serotonin/dopamine transporter ratio
    Marios Politis
    Centre for Neuroscience, Division of Experimental Medicine, Faculty of Medicine, Hammersmith Hospital, Imperial College London, London, United Kingdom
    Mov Disord 26:1997-2003. 2011
    Graft-induced dyskinesias are a serious complication after neural transplantation in Parkinson's disease...
  39. ncbi Stimulation of subthalamic fibre tracts reduces dyskinesias in STN-DBS
    J Herzog
    Department of Neurology, Neurozentrum, Christian Albrechts Universitat Kiel, Kiel, Germany
    Mov Disord 22:679-84. 2007
    ..of patients with subthalamic deep brain stimulation (STN-DBS) is complicated by pharmacologically intractable dyskinesias. Here we report that in three of these patients additional stimulation of a proximal contact located within the ..
  40. ncbi Graft-induced dyskinesias in Parkinson's disease: what is it all about?
    Roger A Barker
    Brain Repair Centre and Department of Neurology, University of Cambridge, Cambridge CB2 0PY, UK
    Cell Stem Cell 7:148-9. 2010
    ..with grafts of fetal ventral mesencephalic tissue has shown some success, but can result in graft-induced dyskinesias (GIDs). Recently in Science Translational Medicine, Politis et al...
  41. pmc Dyskinesias after neural transplantation in Parkinson's disease: what do we know and what is next?
    Marios Politis
    Centre for Neuroscience, Medical Research Council, Hammersmith Hospital, Imperial College London, UK
    BMC Med 8:80. 2010
    ..uncontrolled movements in the absence of dopaminergic medication, so-called off-phase, graft-induced dyskinesias. Notwithstanding the several mechanisms having been proposed, the pathogenesis of this type of dyskinesias ..
  42. ncbi Dyskinesias and dopamine cell replacement in Parkinson's disease: a clinical perspective
    Peter Hagell
    Department of Nursing, Lund University, P O Box 157, SE 221 00 Lund, Sweden
    Brain Res Bull 68:4-15. 2005
    Both increased and decreased dyskinesias have been reported from open label clinical trials of transplantation of human embryonic dopamine rich tissue in Parkinson's disease patients...
  43. ncbi Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson's disease: a double blind video-based analysis
    C Warren Olanow
    Department of Neurology, Mount Sinai School of Medicine, New York, New York 10029 6574, USA
    Mov Disord 24:336-43. 2009
    The objective of this study is to assess dyskinesias in 34 Parkinson's disease patients randomized to receive bilateral fetal nigral transplantation with 4 donors per side (12), 1 donor per side (11), or placebo (11)...
  44. pmc Inversion of dopamine responses in striatal medium spiny neurons and involuntary movements
    Li Liang
    Department of Neurology, School of Medicine, Emory University, Atlanta, Georgia 30322, USA
    J Neurosci 28:7537-47. 2008
    ..These findings point to the fundamental role of dopamine-mediated balance of striatal outputs for normal movement...
  45. ncbi Unawareness of dyskinesias in Parkinson's and Huntington's diseases
    C Vitale
    Department of Neurological Sciences, University Federico II, Naples, Italy
    Neurol Sci 22:105-6. 2001
    We performed a clinical study to evaluate the unawareness of dyskinesias in patients affected by Parkinson's disease (PD) and Huntington's disease (HD)...
  46. ncbi A double-blind crossover, placebo-controlled study of the adenosine A2A antagonist theophylline in Parkinson's disease
    Jaime Kulisevsky
    Movement Disorders Unit, Department of Neurology, Sant Pau Hospital, Autonomous University of Barcelona, Spain
    Clin Neuropharmacol 25:25-31. 2002
    ..of the effect of levodopa in all Unified Parkinson's Disease Rating Scale variables considered, including dyskinesias, maximal levodopa-induced improvement and the duration of the effect of levodopa did not differ significantly ..
  47. ncbi Effect of the D3 dopamine receptor partial agonist BP897 [N-[4-(4-(2-methoxyphenyl)piperazinyl)butyl]-2-naphthamide] on L-3,4-dihydroxyphenylalanine-induced dyskinesias and parkinsonism in squirrel monkeys
    Albert Hsu
    The Parkinson s Institute, 1170 Morse Ave, Sunnyvale, CA 94089, USA
    J Pharmacol Exp Ther 311:770-7. 2004
    ..Parkinson's disease, continued treatment may result in excessive involuntary movements known as L-dopa-induced dyskinesias (LIDs)...
  48. ncbi Health-related quality of life and healthcare utilisation in patients with Parkinson's disease: impact of motor fluctuations and dyskinesias
    R C Dodel
    Department of Neurology, Philipps University Marburg, Germany
    Pharmacoeconomics 19:1013-38. 2001
    ..as changes between akinetic and mobile phases (motor fluctuations) or as abnormal involuntary movements (dyskinesias)...
  49. ncbi ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice
    Nancy Pavon
    Instituto Cajal, Consejo Superior de Investigaciones Cientificas, Madrid, Spain
    Biol Psychiatry 59:64-74. 2006
    ..A major complication of this therapy, however, is the appearance of the abnormal involuntary movements known as dyskinesias. We have developed a model of L-DOPA-induced dyskinesias in mice that reproduces the main clinical features of ..
  50. ncbi Role of serotonin neurons in the induction of levodopa- and graft-induced dyskinesias in Parkinson's disease
    Manolo Carta
    Neurobiology Unit, Wallenberg Neuroscience Center, Department of Experimental Medical Science, Lund University, Lund, Sweden
    Mov Disord 25:S174-9. 2010
    ..This mechanism may also play a role in the development of graft-induced dyskinesias in patients that receive fetal neuron transplants, possibly due to the inclusion of serotonin neurons in the ..
  51. ncbi L-DOPA activates ERK signaling and phosphorylates histone H3 in the striatonigral medium spiny neurons of hemiparkinsonian mice
    Emanuela Santini
    Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden
    J Neurochem 108:621-33. 2009
    ..Our results demonstrate that in the dopamine-depleted striatum, L-DOPA activates ERK signaling specifically in striatonigral MSNs. This regulation may result in ERK-dependent changes in striatal plasticity leading to dyskinesia...
  52. ncbi Mu- and delta-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease
    B Henry
    Manchester Movement Disorder Laboratory, 1.124 Division of Neuroscience, School of Biological Sciences, University of Manchester, Stopford Building, Manchester, M13 9PT, United Kingdom
    Exp Neurol 171:139-46. 2001
    ..These data suggest that specific mu- or delta-opioid receptor antagonists might be applicable clinically in the treatment of levodopa-induced dyskinesia in Parkinson's disease...
  53. ncbi Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology
    R Pahwa
    University of Kansas Medical Center, Kansas City, USA
    Neurology 66:983-95. 2006
    ..5. Preoperative response to levodopa predicts better outcome after DBS of the STN (Level B)...
  54. pmc Altered subthalamo-pallidal synchronisation in parkinsonian dyskinesias
    G Foffani
    Dipartimento di Scienze Neurologiche, Clinica Neurologica, Padiglione Ponti, Ospedale Maggiore Policlinico, Via F Sforza 35, Milano, 20122 Italy
    J Neurol Neurosurg Psychiatry 76:426-8. 2005
    The aim of this work was to study the role of subthalamo-pallidal synchronisation in the pathophysiology of dyskinesias. We recorded local field potentials (LFPs) in a patient with Parkinson's disease and left surgery induced dyskinesias ..
  55. ncbi Docosahexaenoic acid reduces levodopa-induced dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys
    Pershia Samadi
    Centre de Recherche en Neurosciences, Centre Hospitalier Universitaire de Quebec CHUQ, Ste Foy, Quebec, Canada
    Ann Neurol 59:282-8. 2006
    ..study was to investigate the effect of docosahexaenoic acid (DHA), a polyunsaturated fatty acid (omega-3), on levodopa-induced dyskinesias (LIDs) in parkinsonian 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated monkeys.
  56. ncbi Phenotype of striatofugal medium spiny neurons in parkinsonian and dyskinetic nonhuman primates: a call for a reappraisal of the functional organization of the basal ganglia
    Agnes Nadjar
    Centre National de la Recherche Scientifique Unité Mixte de Recherche 5543, Universite Victor Segalen Bordeaux 2, 33076 Bordeaux, France
    J Neurosci 26:8653-61. 2006
    ..Striatofugal pathways are not as segregated in the primate as previously considered...
  57. ncbi High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias
    Alexander Storch
    Department of Neurology, University of Ulm, Ulm, Germany
    Parkinsonism Relat Disord 11:393-8. 2005
    ..3+/-3.8 to 1.7+/-0.9 h per day (p < 0.001) measured by patients' diaries. Dyskinesias, present for 5.0+/-3.3 h per day at baseline, were reduced to 1.4+/-0.8 h per day (p < 0...
  58. ncbi Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease
    P J Hallett
    MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital and Harvard Medical School, 114 16th Street, Charlestown, MA 02129, USA
    Neuropharmacology 48:503-16. 2005
    The development of dyskinesias and other motor complications greatly limits the use of levodopa therapy in Parkinson's disease (PD)...
  59. ncbi Tardive dyskinesia in schizophrenia is associated with prolactin-related sexual disturbances
    Diederik E Tenback
    Psychiatric Center Altrecht, Den Dolder, The Netherlands
    Neuropsychopharmacology 31:1832-7. 2006
    ..This may suggest a shared, pandopaminergic pathological mechanism associated with schizophrenia itself, rather than only a medication effect...
  60. ncbi Cerebral palsy in southern Sweden I. Prevalence and clinical features
    E Nordmark
    Department of Physical Therapy, Lund University, Sweden
    Acta Paediatr 90:1271-6. 2001
    ..4 per 1,000. The distribution according to gestational age, birthweight and subdiagnoses was similar to that in earlier Swedish studies, except for a higher rate of dyskinetic syndromes in this study...
  61. ncbi Familial (idiopathic) paroxysmal dyskinesias: an update
    K P Bhatia
    Department of Clinical Neurology, Institute of Neurology, University College London, United Kingdom
    Semin Neurol 21:69-74. 2001
    ..The paroxysmal dyskinesias share features and therefore may have the same pathophysiological mechanisms as other episodic neurological ..
  62. ncbi Treatments for Parkinson disease--past achievements and current clinical needs
    Werner Poewe
    Department of Neurology, Medical University Innsbruck, Innsbruck, Austria
    Neurology 72:S65-73. 2009
    ..levodopa-related motor complications are only partially effective, rarely abolishing motor fluctuations or dyskinesias. Best results are currently achieved with invasive strategies via subcutaneous (s.c...
  63. ncbi Dyskinesias following neural transplantation in Parkinson's disease
    Peter Hagell
    Section of Restorative Neurology, Wallenberg Neuroscience Center, SE 221 84 Lund, Sweden
    Nat Neurosci 5:627-8. 2002
    Severe dyskinesias during the 'off' phases (periods of increased Parkinson's disease (PD) disability) have been observed following intrastriatal transplantation of human embryonic mesencephalic tissue...
  64. ncbi Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease
    Robert A Hauser
    Department of Neurology, University of South Florida, Tampa, FL 33606, USA
    Arch Neurol 63:1756-60. 2006
    Motor fluctuations and dyskinesias can cause disability and reduce quality of life for patients with Parkinson disease (PD).
  65. pmc Dyskinesias induced by subthalamotomy in Parkinson's disease are unresponsive to amantadine
    M Merello
    Movement Disorders Section, Raul Carrera Institute for Neurological Research, FLENI, Montaneses 2325, Capital Federal, C1428AQK, Buenos Aires, Argentina
    J Neurol Neurosurg Psychiatry 77:172-4. 2006
    b>Dyskinesias are a transient but severe complication of subthalamotomy in some patients.
  66. ncbi Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias
    Frederic Calon
    Molecular Endocrinology and Oncology Research Center, Laval University Medical Center CHUL and Faculty of Pharmacy, Laval University, Ste Foy, Quebec, Canada
    Brain 127:1075-84. 2004
    ..Fourteen levodopa-treated Parkinson's disease patients, of which seven developed dyskinesias and seven did not, were compared with nine controls...
  67. ncbi Comparison of pallidal and subthalamic deep brain stimulation for the treatment of levodopa-induced dyskinesias
    Kenneth A Follett
    Department of Neurosurgery, University of Iowa Hospitals and Clinics, and Iowa City Veterans Administration Medical Center, Iowa City, Iowa 52242, USA
    Neurosurg Focus 17:E3. 2004
    Deep brain stimulation (DBS) can relieve dyskinesias effectively and safely. This modality is applied most commonly in the treatment of dyskinesias associated with levodopa therapy for Parkinson disease...
  68. ncbi Elevated plasma homocysteine levels in L-dopa-treated Parkinson's disease patients with dyskinesias
    Stefano Zoccolella
    Department of Neurological Sciences, University of Bari, Bari, Italy
    Clin Chem Lab Med 44:863-6. 2006
    ..for the development of long-term L-dopa motor complications (such as wearing off and on-off phenomena, and dyskinesias)...
  69. ncbi Enteral levodopa/carbidopa gel infusion for the treatment of motor fluctuations and dyskinesias in advanced Parkinson's disease
    Dag Nyholm
    Department of Neuroscience, Neurology, Uppsala University Hospital, SE 75185, Uppsala, Sweden
    Expert Rev Neurother 6:1403-11. 2006
    ..Motor fluctuations and dyskinesias develop with time as a consequence and can become disabling...
  70. pmc Duration of amantadine benefit on dyskinesia of severe Parkinson's disease
    A Thomas
    Neurophysiopathology, Movement Disorders Centre, Department of Oncology and Neuroscience, Universita G D Annunzio, Chieti Pescara, Pescara, Italy
    J Neurol Neurosurg Psychiatry 75:141-3. 2004
    ..A double-blind study programmed over 12 months was designed to assess the duration of the antidyskinetic effect of amantadine on levodopa induced dyskinesia...
  71. ncbi Management for motor and non-motor complications in late Parkinson's disease
    Daniel K Y Chan
    University of New South Wales, and Department of Aged Care and Rehabilitation, Bankstown Lidcombe Hospital, Australia
    Geriatrics 63:22-7. 2008
    ..The practical evidence-based management of motor and non-motor complications in late PD is discussed...
  72. ncbi Optimizing long-term therapy for Parkinson disease: options for treatment-associated dyskinesia
    Mark Stacy
    Division of Neurology, Duke University Medical Center, Durham, NC 27705, USA
    Clin Neuropharmacol 31:120-5. 2008
    ..In patients with advanced Parkinson disease, it is often not possible to induce periods of good mobility without dyskinesia...
  73. ncbi [Motor symptoms in Parkinson disease]
    Jan Petter Larsen
    Nevrologisk avdeling, Stavanger universitetssjukehus, 4068 Stavanger
    Tidsskr Nor Laegeforen 128:2068-71. 2008
    ..This paper describes how to diagnose Parkinson's disease and the various motor complications and gives recommendations on how to treat the symptoms in these patients...
  74. pmc The first evaluation of brain shift during functional neurosurgery by deformation field analysis
    D Winkler
    Department of Neurosurgery, University of Leipzig, Leipzig, Germany
    J Neurol Neurosurg Psychiatry 76:1161-3. 2005
    ..This case report shows the need to reduce risk factors for intraoperative brain movement and demonstrates the ability of deformation field analysis to quantify this complication...
  75. ncbi The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years
    Mariese A Hely
    Department of Neurology, Westmead Hospital, Westmead, New South Wales, Australia
    Mov Disord 23:837-44. 2008
    ..The challenge is to understand the cellular mechanisms underlying the diverse features of advanced PD that go far beyond a lack of dopamine...
  76. ncbi Nighttime sleep problems and daytime sleepiness in Parkinson's disease
    Dagmar Verbaan
    Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands
    Mov Disord 23:35-41. 2008
    ..No strong relations were found between DS and demographic or clinical variables. The strong relation between NSP and depressive symptoms in PD calls for future studies to explore the nature of this relation...
  77. ncbi Effect of bilateral subthalamic nucleus stimulation on levodopa-unresponsive axial symptoms in Parkinson's disease
    K Yamada
    Department of Neurosurgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
    Acta Neurochir (Wien) 150:15-22; discussion 22. 2008
    ..We retrospectively investigated the effects of bilateral STN stimulation on the axial signs unresponsive to levodopa in Japanese patients with PD...
  78. ncbi Evolution of Parkinson's disease during 4 years of bilateral deep brain stimulation of the subthalamic nucleus
    Karen Østergaard
    Department of Neurology, Aarhus University Hospital, Nørrebrogade, Aarhus C, Denmark
    Mov Disord 21:624-31. 2006
    ..Five patients developed dementia. Severe adverse events were not observed...
  79. ncbi Paradoxical kinesia at war
    Ilana Schlesinger
    Department of Neurology, Rambam Health Care Campus, Haifa, Israel
    Mov Disord 22:2394-7. 2007
    ..002), and depression (P < 0.01) as compared with their performance before the war. Paradoxical kinesia is uncommon, even in the face of danger. Visual, but not auditory, triggers appear to be needed to prompt its occurrence...
  80. ncbi Patient evaluation of a home diary to assess duration and severity of dyskinesia in Parkinson disease
    Robert A Hauser
    Parkinson s Disease and Movement Disorders Center, University of South Florida and Tampa General Healthcare, Tampa, FL 33606, USA
    Clin Neuropharmacol 29:322-30. 2006
    ....
  81. ncbi Chronic high-frequency stimulation of the subthalamic nucleus and L-DOPA treatment in experimental parkinsonism: effects on motor behaviour and striatal glutamate transmission
    Paolo Gubellini
    Equipe IC2N, Institut de Biologie du Developpement de Marseille Luminy IBDML, UMR6216, 31, Chemin Joseph Aiguier CNRS Université de la Méditerranée, 13402 Marseille, Cedex 20, France
    Eur J Neurosci 24:1802-14. 2006
    ..The interaction between these two treatments provides further evidence that striatal glutamatergic hyperactivity is a pathophysiological correlate of akinesia rather than LID...
  82. ncbi Bilateral effects of unilateral subthalamic nucleus deep brain stimulation in advanced Parkinson's disease
    Sun J Chung
    Center for Parkinsonism and Other Movement Disorders, Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
    Eur Neurol 56:127-32. 2006
    ..No patient exhibited permanent side effects. These findings indicate that unilateral STN-DBS may be a reasonable surgical procedure for selected PD patients who have markedly asymmetric parkinsonism...
  83. ncbi Efficacy and safety of simultaneous bilateral pallidotomy in advanced Parkinson's disease
    Sun J Chung
    Department of Neurology, Center for Parkinsonism and Other Movement Disorders, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
    Eur Neurol 56:113-8. 2006
    ....
  84. ncbi Perceptual factors contribute to akinesia in Parkinson's disease
    B Ballanger
    Laboratoire Performance Motricité et Cognition, University of Poitiers, Poitiers, France
    Exp Brain Res 179:245-53. 2007
    ..This suggests that the high-level perceptual deficits observed in the present study do not have a dopaminergic origin...
  85. ncbi [Medical treatment of Parkinson's disease]
    D Waldvogel
    Neurologische Praxis Luzern, Hirslanden Klinik St Anna, Luzern
    Ther Umsch 64:15-20. 2007
    ..However, proper treatment of PD has to address the non-motor symptoms and the complications of therapy as well...
  86. ncbi High-frequency stimulation of the subthalamic nucleus potentiates L-DOPA-induced neurochemical changes in the striatum in a rat model of Parkinson's disease
    Abid Oueslati
    Developmental Biology Institute of Marseille Luminy, Unite Mixte de Recherche 6216, Centre National de la Recherche Scientifique Université de la Méditerranée, 13402 Marseille Cedex 20, France
    J Neurosci 27:2377-86. 2007
    ..Only animals showing severe L-DOPA-induced dyskinesias (LIDs) were included, and STN-HFS was applied for 5 d at an intensity efficient for alleviating akinesia ..
  87. ncbi Prevalence and treatment strategies of dyskinesia in patients with Parkinson's disease
    T Muller
    Department of Neurology, St Josef Hospital, Ruhr University, Bochum, Germany
    J Neural Transm 114:1023-6. 2007
    ..Treatment of dyskinesia was looked upon as not satisfactory, fractionating of levodopa dose was used as first choice therapeutic option of dyskinesia...
  88. ncbi OFF-off rebound dyskinesia in subthalamic nucleus deep brain stimulation of Parkinson's disease
    Matthew A Brodsky
    Department of Neurology, Oregon Health and Science University, and Parkinson s Disease Research, Education and Clinical Care Center, Portland VA Medical Center, Portland, Oregon, USA
    Mov Disord 21:1487-90. 2006
    A 61-year-old man with Parkinson's disease (PD), motor fluctuations, and dyskinesias underwent bilateral implantation of deep brain stimulation (DBS) electrodes in the subthalamic nucleus (STN)...
  89. ncbi Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome
    Angelo Antonini
    Parkinson Institute, Istituti Clinici di Perfezionamento, Milan, Italy
    Mov Disord 22:1145-9. 2007
    ..05). Two patients withdrew for adverse events. Our results demonstrate that a satisfactory therapeutic window can be achieved and maintained for several months in advanced PD patients...
  90. ncbi Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease
    Andrzej Dekundy
    Preclinical R and D, Merz Pharmaceuticals GmbH, Eckenheimer Landstr 100, 60318 Frankfurt am Main, Germany
    Brain Res Bull 69:318-26. 2006
    ..However, mGluR5 antagonists may prove useful for the symptomatic treatment of L-DOPA-induced dyskinesia...
  91. ncbi New therapies for the treatment of Parkinson's disease: adenosine A2A receptor antagonists
    Annalisa Pinna
    CNR Institute of Neuroscience Cagliari section, Italy
    Life Sci 77:3259-67. 2005
    ..have shown that a low dose of L-DOPA plus KW-6002 produced symptomatic relief no different from that produced by an optimal dose of L-DOPA alone, whereas dyskinesias were reduced rendering this class of compounds particularly attractive.
  92. ncbi Dyskinesias and grip control in Parkinson's disease are normalized by chronic stimulation of the subthalamic nucleus
    Roland Wenzelburger
    Department of Neurology, Christian Albrechts University, Kiel, Germany
    Ann Neurol 52:240-3. 2002
    Deep-brain stimulation of the subthalamic nucleus appears to reduce levodopa-induced dyskinesias, but whether this effect is caused by the reduction of the total levodopa ingestion or represents a direct effect on the motor system is ..
  93. ncbi Motor complications in Parkinson disease: a prospective follow-up study
    Pedrox J García Ruiz
    Department of Neurology, Fundacion Jimenez Diaz, Madrid, Spain
    Clin Neuropharmacol 27:49-52. 2004
    ..3 points; year 3, 22.6 points; year 4, 24.9 points; year 5, 29.5 points). Motor fluctuations, dyskinesias, and freezing also increased after year 3 from 10%, 16%, and 8% respectively to 35%, 32%, and 27% at year 5...
  94. ncbi [Motor impairment, in patients with severe Parkinson's disease, associated with dopaminergic hyperstimulation (entacapone)]
    J Vaamonde
    , Complejo Hospitalario de Ciudad Real
    Neurologia 16:81-4. 2001
    ..with Parkinson's disease (PD) treated chronically with levodopa, with daily severe motor fluctuations and dyskinesias. PATIENTS AND METHODS: We introduced entacapone (200 mg added to every dose of levodopa) to 8 parkinsonian ..
  95. ncbi Dopaminergic hypersensitivity in patients with Parkinson disease and migraine
    Esther Cubo
    Sanatorio del Rosario, Clinica de la Zarzuela, Department of Neurology, Madrid, Spain
    Clin Neuropharmacol 27:30-2. 2004
    ..These data support the hypothesis that migraine may be associated with dopaminergic hypersensitivity...
  96. ncbi Effects of pulsatile L-DOPA treatment in the double lesion rat model of striatonigral degeneration (multiple system atrophy)
    N Stefanova
    Department of Neurology, University Hospital of Innsbruck, Innsbruck, Austria
    Neurobiol Dis 15:630-9. 2004
    ..Striatal FosB/Delta FosB up-regulation in SND and PD rats correlated with the severity of L-DOPA-induced dyskinesias. Pulsatile L-DOPA administration in the double lesion SND rat model replicates salient features of the human ..
  97. ncbi Adenosine receptors and L-DOPA-induced dyskinesia in Parkinson's disease: potential targets for a new therapeutic approach
    Fabio Blandini
    Laboratory of Functional Neurochemistry, Neurological Institute C Mondino, Pavia, Italy
    Exp Neurol 184:556-60. 2003
  98. ncbi Long-term L-DOPA therapy: challenges to our understanding and for the care of people with Parkinson's disease
    John G Nutt
    Department of Neurology, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, OP32, Portland, OR 97201 3098, USA
    Exp Neurol 184:9-13. 2003
  99. ncbi Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease
    Fabrizio Stocchi
    Institute of Neurology and Neuromed, University La Sapienza, Viale dell Universita 30, 00185 Rome, Italy
    Brain 125:2058-66. 2002
    ..This study indicates that continuous lisuride infusion can be beneficial for patients with advanced Parkinson's disease and reverse established motor fluctuations and dyskinesia...
  100. ncbi Levodopa pharmacokinetics and dyskinesias: are there sex-related differences?
    P Martinelli
    Dipartimento di Scienze Neurologiche, Universita di Bologna, Bologna, Italy
    Neurol Sci 24:192-3. 2003
    ..the potential sex-related differences in levodopa pharmacokinetics and their relation with the presence of dyskinesias in a group of 115 patients (67 men, 49 women) with Parkinson's disease...
  101. ncbi Subthalamic nucleus stimulation for Parkinson's disease preferentially improves akinesia of proximal arm movements compared to finger movements
    Roland Wenzelburger
    Department of Neurology, Christian Albrechts Universitat Kiel, Kiel, Germany
    Mov Disord 18:1162-9. 2003
    ..Other akinesia items and the time for build-up of lifting force were equally improved in both conditions. This suggests that routine STN-DBS might not be equally effective on all aspects of fine motor functions...

Research Grants62

  1. Principles of Therapy in Cerebellar Disease: Explorations in Ion Channel Mutants
    JOHN SAMUEL STAHL; Fiscal Year: 2013
    ....
  2. Autoimmunity Against Novel Antigens in Neuropsychiatric Dysfunction
    Josep O Dalmau; Fiscal Year: 2013
    ....
  3. Synaptic autoimmunity in disorders of memory, behavior, cognition and psychosis
    Josep Dalmau; Fiscal Year: 2010
    ....
  4. A Phase II Trial of Levodopa in Angelman Syndrome
    Wen Hann Tan; Fiscal Year: 2013
    ....
  5. Molecular Mechanisms Controlling Formation of Basal Ganglia Circuitry
    KENNETH J CAMPBELL; Fiscal Year: 2013
    ....
  6. CRCNS: Propagation of beta oscillations in cortico-basal ganglia-thalamic loop
    Michelle M McCarthy; Fiscal Year: 2013
    ..its efficacy is limited by the "wearing off" phenomenon and its potential to engender potentially disabling dyskinesias ...
  7. Characterization of Striatal Nitric Oxide Signaling
    Anthony West; Fiscal Year: 2009
    ..Parkinson's disease (PD), but lose effectiveness with time and produce debilitating side effects such as dyskinesias. Recent studies suggest that alterations in striatal cyclic nucleotide homeostasis are critically involved in ..
  8. Roles of Gsh1 &Gsh2 in Telencephalic Neurogenesis
    KENNETH J CAMPBELL; Fiscal Year: 2012
    ..abstract_text> ..
  9. Prevalence of FMRI Expansions in Movement Disorders
    Deborah A Hall; Fiscal Year: 2010
    ..These illnesses represent an important public health problem as they cause morbidity and mortality in our aging population. ..
  10. ROLE OF DOPAMINE RECEPTORS IN PRIMARY FOCAL DYSTONIAS
    Morvarid Karimi; Fiscal Year: 2013
    ..Selective ligands for D2 R, D3 R and D1-like receptors could be used to investigate the pathophysiology of dyskinesias in PD given their likely role in development of this disabling side effect of PD therapy...
  11. Reducing Dyskinesia in Parkinson Disease with Omega-3 Fatty Acids
    KATHRYN ANNE CHUNG; Fiscal Year: 2012
    DESCRIPTION (provided by applicant): Levodopa induced dyskinesias (LID) are involuntary, abnormal movements that occur in most patients with Parkinson disease(PD) as a consequence of chronic use of the most effective symptomatic drug, ..
  12. Paraneoplastic Disorders of the CNS: Autoantigen Profiling
    Josep O Dalmau; Fiscal Year: 2013
    ..dementia with CSF inflammatory/autoimmune features, 2) opsoclonus-myoclonus-ataxia, 3) acute encephalitis with dyskinesias, and 4) encephalitis with refractory-relapsing seizures...
  13. Role of Endocannabinoids in Levodopa-Induced Dyskinesias
    Andrea Giuffrida; Fiscal Year: 2012
    ..therapy - the gold standard in Parkinson's disease (PD) treatment - causes disabling motor complications (dyskinesias) that are largely resistant to available drugs...
  14. L-DOPA-induced dyskinesias and dysregulation of striatopallidal neurons
    STEVEN MICHAEL GRAVES; Fiscal Year: 2013
    ..receptors exclusively activated by designer drugs (DREADDs) in Parkinson's disease (PD) and L-DOPA-induced dyskinesias (LIDs)...
  15. Kinesia-D: Ambulatory PD Dyskinesia Monitor for Drug Therapy Titration
    THOMAS OLIVER MERA; Fiscal Year: 2013
    ..testing and/or the patient's subjective assessment of and ability to distinguish between PD tremor, dyskinesias, and voluntary movements throughout the day...
  16. A2AR/mGluR5 Antagonist Combination Antiparkinsonian Therapy in MPTP Monkeys
    James Bogenpohl; Fiscal Year: 2010
    ..Current long term dopamine replacement therapies result in dyskinesias and other debilitating side effects...
  17. Nigrostriatal Tract Reconstruction
    JOHN RICHARD SLADEK; Fiscal Year: 2010
    ..In some clinical trials patients who initially showed some level of motor improvement eventually showed dyskinesias that are postulated to be due to uncontrolled or excessive release of dopamine by the grafts...
  18. Aberrant Synaptic Plasticity: Impact on Dopamine Graft Outcome
    KATHY STEECE STEECE-COLLIER; Fiscal Year: 2011
    ..As the disease progresses, therapeutic benefit can wane, and significant side effects such as dyskinesias can impose additional limitations...
  19. Aging and Parkinson's Disease: Models of Therapeutics and Neurologic Comorbidity
    Timothy J Collier; Fiscal Year: 2013
    ..with development of adverse consequences of disease and treatment (such as depression and therapy-induced dyskinesias) and mechanisms associated with translational therapeutics (such as subthalamic nucleus DBS and progenitor ceU ..
  20. Gene expression regulatory circuitry and microRNAs in midbrain dopamine neurons
    Asa Abeliovich; Fiscal Year: 2013
    ..with midbrain dopamine neurons (mDNs), including Parkinson's disease (PD), schizophrenia, autism, dyskinesias, and drug addiction...
  21. Ischemic Spasticity: Modulation by GAD65 Gene Delivery
    Martin Marsala; Fiscal Year: 2010
    ..intrastriatal injections of adeno-associated virus encoding GAD65 gene is effective in suppressing parkinsonian dyskinesias and is associated with an increase in local GABA release...
  22. [18F]FPEB Studies of the mGluR5 Receptor and Methamphetamine Abuse
    ROBERT MICHAEL KESSLER; Fiscal Year: 2013
    ..Huntington's disease, depression, and anxiety disorders as well as playing an important role in motor dyskinesias in Parkinsons disease...
  23. Development of Novel Therapies for Levodopa-induced Dyskinesia in Parkinson's Dis
    Nurulain T Zaveri; Fiscal Year: 2010
    ..Our proposal investigates a new, relatively unexplored target for PD therapy and L-Dopa induced dyskinesias, and proposes to develop novel drug candidates against this target, to validate this target as being suitable ..
  24. Frontal-Subcortical Development, Movement Abnormalities, and Risk for Psychosis
    Vijay A Mittal; Fiscal Year: 2013
    ..patterns of grey and white matter in the FSC system characterize prodromal populations and result in dyskinesias and/or Parkinsonisms) and if developmental abnormalities in this system and SMAs (a potential biomarker that ..
  25. Functional Brain Networks: A Novel Approach to Address Clinical Challenges in PD
    David Eidelberg; Fiscal Year: 2013
    ..Project 1 addresses the serious clinical problem of levodopa-induced dyskinesias, which ultimately affect nearly all PD patients...
  26. Mechanisms of nicotine-mediated decrease in L-dopa induced-dyskinesias
    Maryka Quik; Fiscal Year: 2013
    ..DESCRIPTION (provided by applicant): Our overall aim is to elucidate the mechanisms that underlie L-dopa-induced dyskinesias (LIDs) and to develop anti-dyskinetic strategies, with a focus on the nicotinic cholinergic system...
  27. Kinesia-D: Ambulatory Parkinson's Disease Dyskinesia Monitor for Drug Therapy Tit
    THOMAS OLIVER MERA; Fiscal Year: 2011
    ..with continuous monitoring capabilities to detect and quantify the severity of levodopa-induced choreatic dyskinesias, or irregular rapid involuntary movements, in Parkinson's disease (PD)...
  28. Manipulating Gene Expression in the Dyskinesias of Parkinson's Disease
    Stella M Papa; Fiscal Year: 2013
    ..of dopaminergic therapy in Parkinson's disease, namely the development of involuntary movements named dyskinesias. The mechanisms underlying dyskinesias remain unknown, and we lack specific and effective treatments to ..
  29. Validation of PPARgamma agonists as anti-dyskinetic drugs
    Alex Anthony Martinez; Fiscal Year: 2013
    ..associated with disabling side effects consisting of uncontrolled involuntary movements known as L-DOPA-induced dyskinesias (LID)...
  30. Functional circuit disorders of sensory cortex in ASD and RTT
    Gregory C Carlson; Fiscal Year: 2012
    ..Symptoms can include stereotypic dyskinesias, autistic features, including language delay and regression, breathing abnormalities, and abnormal central EEG ..
  31. EMBRYONIC DOPAMINE CELL IMPLANTS FOR PARKINSONISM
    Curt Freed; Fiscal Year: 2005
    ..Some of the transplanted patients develop dyskinesias (abnormal, excess movements) even off agonist therapy, starting typically more than one year after surgery...
  32. Cortical contributions to basal ganglia disorders
    PETER STRICK; Fiscal Year: 2006
    ..These injections produce reversible dyskinesias, hyperactivity, attention deficits or stereotypes, depending upon the location of the injection site...
  33. Translational Foundation of Adenosine Antagonist Use for Dyskinesias
    Michael A Schwarzschild; Fiscal Year: 2010
    ..Preclinical evidence that A2A antagonists reliably reduce motor disability without producing dyskinesias (motor complications of standard L-dopa therapy) in parkinsonian primates has led to encouraging initial ..
  34. Evaluating BMY-14802 as an anti-dyskinesia treatment in the 6-OHDA rat model of P
    MELANIE PAQUETTE; Fiscal Year: 2009
    ..of people who take L-DOPA eventually develop debilitating side effects, abnormal involuntary movements called dyskinesias, which may affect the limbs, body, and or face...
  35. Focal Dopamine Indicated in Dyskinesias in MPTP Monkeys
    Krystof S Bankiewicz; Fiscal Year: 2010
    The broad aim of this proposal is to test the hypothesis that L-dopa-induced dyskinesias (LID) in Parkinson's disease (PD) arise at least in part from non-uniform dopaminergic denervation of the striatum, whereby islands of ..
  36. STUDIES IN ORAL PHARYNGEAL REFLEXES
    Scott Chandler; Fiscal Year: 1993
    ..The importance of jaow and tongue control in prosthodontics is becoming more evident. Dyskinesias involving the jaw and tongue are also manifest in tardive dyskinesia, senility, stroke and in comatose patients...
  37. ORAL PHARYNGEAL REFLEXES
    Louis Goldberg; Fiscal Year: 1992
    ..The importance of jaow and tongue control in prosthodontics is becoming more evident. Dyskinesias involving the jaw and tongue are also manifest in tardive dyskinesia, senility, stroke and in comatose patients...
  38. PDRemote: Automated Telehealth Diagnostics for Remote Parkinson's Monitoring
    Joseph P Giuffrida; Fiscal Year: 2010
    ..Major PD symptoms include tremor, bradykinesia, and rigidity. Additionally, dyskinesias or wild involuntary movements as a side effect of drug therapy can be a motor complication...
  39. STREP, HOST FACTORS, AUTOANTIBODIES & TOURETTE SYNDROME
    Harvey Singer; Fiscal Year: 2000
    ..children with TS and b) after intrastriatal injection of purified serum IgG from TS patients, rodents developed dyskinesias associated with antibody binding to striatal neurons...
  40. Functional Studies of Subtypes of Parkinson's Diseasee
    Xuemei Huang; Fiscal Year: 2007
    ..PD (PDT) generally has better long-term motor outcome with fewer motor fluctuations, less levodopa-induced dyskinesias, a slower rate of progression, and fewer cognitive deficits when compared with akinetic-rigid-predominant PD (..
  41. HALOPERIDOL AND ATTENTIONAL LEARNING IN AUTISTIC CHILDRE
    Magda Campbell; Fiscal Year: 1991
    ..autistic children who require pharmacotherapy, are sought because of the high incidence of neuroleptic-related dyskinesias. (2) We also wish to continue our long-term prospective study of haloperidol in autistic children: to assess ..
  42. PET IN HYPERKINETIC DISORDERS--A MULTICENTER STUDY
    David Eidelberg; Fiscal Year: 2001
    ..This approach may have great utility in evaluating new interventions for the treatment of the hyperkinetic movement disorders. ..
  43. TorsinA function and dystonia-related dysfunction in developing and mature CNS
    William T Dauer; Fiscal Year: 2013
    ....
  44. Advanced Technology and Tools for DBS Programming for Speech Functionality
    Craig van Horne; Fiscal Year: 2009
    ..after DBS were noted, they were typically minimal and more variable than seen in akinesia, rigidity, and dyskinesias." This project's goal is to develop an inexpensive portable device and software tools that will ..
  45. GABA AGONIST THERAPY IN TARDIVE DYSKINESIA
    Carol Tamminga; Fiscal Year: 1999
    ..a therapeutic effect of clozapine in TD and now are seeking to understand whether clozapine improves dyskinesias in TD through diminishing these same neuroleptic-induced GABAergic changes in the substantia nigra pars ..
  46. DEEP BRAIN STIMULATION--COGNITION/MOTIVATION/MOOD IN PD
    Marjan Jahanshahi; Fiscal Year: 2005
    ..of Parkinson's disease (PD), particularly improving akinesia and rigidity and reducing levodopa-induced dyskinesias. Neuropsychological investigations have shown that such beneficial effects of DBS on motor function are ..
  47. NEUROLEPTIC-INDUCED DYSKINESIAS AND DYSTONIAS
    Gaylord Ellison; Fiscal Year: 1992
    ..to pursue this model, which we argue is presently the best viable rodent model of neuroleptic-induced oral dyskinesias, by studying how drugs which affect dopamine or cholinergic receptors, as well as other pharmacological agents, ..
  48. Levodopa Pharmokinetic Optimization by Metal Coordination
    Thomas Piccariello; Fiscal Year: 2009
    ..often experience a need to maintain plasma drug levels within a narrowing therapeutic window in order to avoid dyskinesias, associated with high drug levels, and off periods that occur when levels are low...
  49. NEUROIMAGING OF HYPERKINETIC MOVEMENT DISORDERS
    Michael Hutchinson; Fiscal Year: 2001
    ..Validation of this approach will mediate between existing theories of cortical-subcortical interactions, and may suggest possible surgical or pharmacological intervention in these disorders. ..
  50. GLUTAMATE IN PARKINSON'S DISEASE
    J Greenamyre; Fiscal Year: 2003
    ..3. Compare the development and severity of dyskinesias in de novo parkinsonian monkeys treated chronically with (1) levodopa alone, or (2) a combination of levodopa ..
  51. SIGNALING MECHANISMS IN DOPAMINE RECEPTOR SYNERGISM
    Yuan Luo; Fiscal Year: 2007
    ..the expression or progression of diverse neurological and psychiatric diseases, including Parkinson disease, dyskinesias, schizophrenia, drug addiction, and Tourette disorder...
  52. Levodopa dyskinesia and striatal neuroplasticity
    Christine Konradi; Fiscal Year: 2007
    ..L-DOPA treatment are eventually afflicted with motor fluctuations and abnormal, involuntary movements known as dyskinesias. L-DOPA-induced dyskinesias can become more disabling than Parkinson's disease itself...
  53. NOVEL ANTIPSYCHOTICS AND STEREOTYPED MOVEMENT DISORDER
    Karl Newell; Fiscal Year: 2007
    ..of adaptive, goaloriented actions? And (4) Are there differences between the short and long term effects of atypical antipsychotics on aberrant behavior, abnormal movements, and goal-oriented motor task performance? ..
  54. Adapative Wireless Computer Mouse for Movement Disorders
    JOSEPH GIUFFRIDA; Fiscal Year: 2006
    ..Major symptoms of PD include tremor, dyskinesias, bradykinesia, and rigidity. ET produces tremors that affect motor function...
  55. Deep Brain Stimulation Using Microactuated Microprobes
    Jit Muthuswamy; Fiscal Year: 2006
    ..It is also a promising therapy for epilepsy, dyskinesias, obsessive-compulsive and anxiety disorder...
  56. DEEP BRAIN STIMULATION FOR PARKINSONS DISEASE
    JERROLD VITEK; Fiscal Year: 2005
    ..of patients experience worsening of their parkinsonism and develop incapacitating motor fluctuations and dyskinesias. To deal with this, attention has been directed to surgical procedures, especially ablative therapies, e.g...
  57. Wireless Movement Disorder Monitor
    JOSEPH GIUFFRIDA; Fiscal Year: 2009
    ..Three major PD symptoms that affect quality of life include tremor, bradykinesia, and dyskinesias. These symptoms are often responsible for functional disability and social embarrassment...
  58. Continuous Dopaminergic Stimulation: Parkinson's Disease
    Thomas Smith; Fiscal Year: 2005
    ..as to adverse effects of treatment of PD and may also contribute to progression of motor side effects such as dyskinesias. Continuous dopaminergic stimulation has therefore been considered an important therapeutic goal...
  59. ALTERED SEROTONIN SIGNAL TRANSDUCTION IN DYSKINESIAS
    William Wolf; Fiscal Year: 2000
    ..term objective of this research is to determine the neurochemical mechanisms underlying antipsychotic-induced dyskinesias. Antipsychotics, such as haloperidol, are widely used in the treatment of schizophrenia and in agitated elderly ..
  60. ROLE OF VENTROLATERAL THALAMUS IN CEREBELLAR TREMOR
    JERROLD VITEK; Fiscal Year: 1992
    ..These studies may lead to the development of new therapeutic strategies for the treatment of movement disorders...
  61. ABNORMAL MOVEMENTS AND PHARMACOLOGY OF THE FOREBRAIN
    S Snodgrass; Fiscal Year: 1980
    ..Since this recovery is reversible with PCPA (a blocker of serotonin synthesis) it seems to depend upon restoration of 5-HT neuronal function, most likely in the substantia nigra...
  62. Molecular Basis of D1 and D2 Priming
    Alexia Pollack; Fiscal Year: 2003
    Response fluctuations and dyskinesias are often associated with chronic dopamine-replacement therapy for Parkinson's disease (PD). It is these 'side-effects' that severely limit the long-term usefulness of this therapy...